Henry Schein, Inc. (NASDAQ:HSIC) Director Sells $184,988.16 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This represents a 9.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $70.45 on Friday. The firm has a 50-day moving average price of $74.83 and a 200 day moving average price of $72.61. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $8.75 billion, a PE ratio of 28.99, a price-to-earnings-growth ratio of 2.13 and a beta of 0.90. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.49.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.66 EPS. Research analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Wells Fargo & Company initiated coverage on Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price on the stock. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and upped their target price for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Mizuho initiated coverage on Henry Schein in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 price target for the company. Finally, UBS Group cut their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.10.

Institutional Trading of Henry Schein

Hedge funds have recently modified their holdings of the company. Palestra Capital Management LLC bought a new stake in Henry Schein during the 4th quarter worth approximately $182,988,000. Lyrical Asset Management LP bought a new stake in shares of Henry Schein in the 4th quarter valued at about $126,655,000. Norges Bank acquired a new stake in shares of Henry Schein in the 4th quarter valued at approximately $103,301,000. Steadfast Capital Management LP grew its holdings in Henry Schein by 254.2% during the fourth quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company’s stock valued at $113,336,000 after purchasing an additional 1,175,408 shares during the period. Finally, Holocene Advisors LP acquired a new stake in Henry Schein in the third quarter worth $58,319,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.